Insider · CIK 0001495411

Goldan Keith A.

Reports to the SEC for 5 companies · NEW YORK, NY

sec.gov

Transactions

Companies

Filings

CIK

0001495411

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-06-01	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−1,177 sh	$18.99	−$22.4K	139,252
2026-04-01	ABEOABEONA THERAPEUTICS INC.A Award	Director	AAward	+32.8K sh	—	—	32,751
2026-02-09	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−3,410 sh	$21.03	−$71.7K	140,429
2026-02-06	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−2,082 sh	$20.62	−$42.9K	143,839
2026-02-04	SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+118K sh	$20.43	+$2.41M	118,000
2026-02-04	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+30.8K sh	—	—	145,921
2026-02-04	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+21.5K sh	—	—	115,171
2026-01-30	SNDXSyndax Pharmaceuticals IncJ Other	Chief Financial Officer	JOther	+1,219 sh	$8.48	+$10.3K	93,671
2025-12-01	SNDXSyndax Pharmaceuticals IncG Gift	Chief Financial Officer	GGift	−1,224 sh	—	—	92,452
2025-07-31	SNDXSyndax Pharmaceuticals IncJ Other	Chief Financial Officer	JOther	+1,226 sh	$8.43	+$10.3K	93,676
2025-07-16	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−1,296 sh	$9.29	−$12K	92,450
2025-05-19	SNDXSyndax Pharmaceuticals IncP Purchase	Chief Financial Officer	PPurchase	+3,000 sh	—	—	93,746
2025-02-10	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−3,777 sh	$15.50	−$58.6K	90,746
2025-02-05	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+23.4K sh	—	—	94,523
2025-02-05	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+18.5K sh	—	—	71,123
2025-02-05	SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+111K sh	$14.65	+$1.62M	110,500
2024-06-14	SNDXSyndax Pharmaceuticals IncP Purchase	Chief Financial Officer	PPurchase	+1,250 sh	$20.03	+$25K	52,623
2024-02-07	SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+70K sh	$22.28	+$1.56M	70,000
2024-02-07	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+35K sh	—	—	39,673
2024-02-07	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+11.7K sh	—	—	51,373
2024-01-31	SNDXSyndax Pharmaceuticals IncJ Other	Chief Financial Officer	JOther	+1,183 sh	$17.42	+$20.6K	4,673
2023-07-31	SNDXSyndax Pharmaceuticals IncJ Other	Chief Financial Officer	JOther	+862 sh	$18.12	+$15.6K	3,490
2023-06-13	SNDXSyndax Pharmaceuticals IncS Sale	Chief Financial Officer	SSale	−577 sh	$22.31	−$12.9K	2,628
2023-02-02	SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+110K sh	$28.55	+$3.14M	110,000
2022-06-13	SNDXSyndax Pharmaceuticals IncA Award	Chief Financial Officer	AAward	+3,205 sh	—	—	3,205
2022-06-13	SNDXSyndax Pharmaceuticals Inc · Stock Options (Right to buy)A Award	Chief Financial Officer	AAward	+230K sh	$15.60	+$3.59M	230,000
2022-03-16	OptiNose, Inc.S Sale	Chief Financial Officer	SSale	−4,617 sh	$2.11	−$9,741.87	141,726
2022-01-11	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+66.2K sh	—	—	66,185
2022-01-11	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+56.7K sh	—	—	146,343
2022-01-11	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+85.1K sh	—	—	85,095
2021-12-16	OptiNose, Inc.S Sale	Chief Financial Officer	SSale	−580 sh	$1.64	−$951.2	89,613
2021-09-16	OptiNose, Inc.S Sale	Chief Financial Officer	SSale	−578 sh	$2.79	−$1,612.042	90,193
2021-06-17	OptiNose, Inc.S Sale	Chief Financial Officer	SSale	−576 sh	$3.73	−$2,148.48	90,771
2021-03-15	OptiNose, Inc.S Sale	Chief Financial Officer	SSale	−2,304 sh	$3.92	−$9,031.68	91,347
2021-03-04	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+53.3K sh	—	—	63,084
2021-03-04	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+80K sh	$3.51	+$281K	80,000
2020-09-23	OptiNose, Inc.P Purchase	Chief Financial Officer	PPurchase	+2,500 sh	$3.90	+$9,742.5	9,751
2020-03-06	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+45.9K sh	$5.41	+$248K	45,850
2020-03-06	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+30.6K sh	—	—	37,328
2020-03-06	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+45.9K sh	$5.41	+$248K	45,850
2020-03-06	OptiNose, Inc.Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+30.6K sh	—	—	30,567
2019-12-31	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+2,695 sh	$6.13	+$16.5K	6,761
2019-06-28	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+941 sh	$5.64	+$5,307.24	4,066
2019-02-28	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+82.5K sh	—	—	82,500
2018-06-29	OptiNose, Inc.A Award	Chief Financial Officer	AAward	+3,125 sh	$13.60	+$42.5K	3,125
2017-10-12	OptiNose, Inc.Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+72.2K sh	—	—	72,197
2016-03-01	Fibrocell Science, Inc.Option to Purchase Common StockA Award	SVP and CFO	AAward	+200K sh	—	—	200,000
2015-08-11	Fibrocell Science, Inc.P Purchase	SVP and CFO	PPurchase	+2,000 sh	$6.33	+$12.7K	2,000
2014-02-21	NUPATHE INC.Stock option (right to buy)D Disposition to Issuer	CFO and SVP	DDisposition to Issuer	−99.7K sh	$4.88	−$487K	0
2014-02-21	NUPATHE INC.U Disposition from Tender	CFO and SVP	UDisposition from Tender	−18.9K sh	$6.80	−$128K	0

Recent filings

Accepted (ET)
Jun 24
Goldan Keith A.0001193125-26-253603
SEC(opens sec.gov)
Apr 74
Goldan Keith A.0001493152-26-015456
SEC(opens sec.gov)
Feb 104
Goldan Keith A.0001193125-26-043813
SEC(opens sec.gov)
Feb 64
Goldan Keith A.0001193125-26-041497
SEC(opens sec.gov)
Dec 14
Goldan Keith A.0001193125-25-303941
SEC(opens sec.gov)
Aug 74
Goldan Keith A.0000950170-25-105258
SEC(opens sec.gov)
Jul 184
Goldan Keith A.0000950170-25-096948
SEC(opens sec.gov)
May 194
Goldan Keith A.0000950170-25-074304
SEC(opens sec.gov)
Feb 124
Goldan Keith A.0000950170-25-019005
SEC(opens sec.gov)
Feb 74
Goldan Keith A.0000950170-25-016389
SEC(opens sec.gov)
Jun 174
Goldan Keith A.0001562180-24-005118
SEC(opens sec.gov)
Feb 94
Goldan Keith A.0001562180-24-001222
SEC(opens sec.gov)

Companies

Address

730 THIRD AVENUE FLOOR 9

NEW YORK, NY, 10017